SCHEMBL6315265

SCHEMBL6315265

C=CCNC(=O)c1c(-c2ccc(C)s2)noc1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA4 P22748 1/20 0.45
CA7 P43166 1/20 0.45
ALOX15 P16050 2/20 0.40
SMN1; SMN2 Q16637 6/20 0.40
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
STAT1 P42224 1/20 0.40
HPGD P15428 3/20 0.39
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 5/20 0.38
POLB P06746 1/20 0.37
TP53 P04637 2/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 2/20 0.37
CYP1A2 P05177 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322750 0.87 CA1 (0.44) CA1CA2CA4CA7ALOX15
SCHEMBL6318480 0.87 CA1 (0.60) CA1CA2CA4CA7ALOX15
SCHEMBL6324224 0.83 CA1 (0.44) CA1CA2CA4CA7SMN1; SMN2
SCHEMBL6315560 0.82 CA1 (0.43) CA1CA2CA4CA7SMN1; SMN2
SCHEMBL6317644 0.81 GAA (0.44) CA1CA2CA4CA7ALOX15
SCHEMBL6316101 0.81 CA1 (0.42) CA1CA2CA4CA7ALOX15
SCHEMBL6320945 0.81 KMT2A (0.49) CA1CA2CA4CA7SMN1; SMN2
SCHEMBL6317603 0.81 GAA (0.53) SMN1; SMN2RAB9ANPC1ALDH1A1MAPT
SCHEMBL6321826 0.81 GAA (0.43) CA1CA2CA4CA7ALOX15
SCHEMBL6315672 0.80 POLB (0.41) ALOX15SMN1; SMN2RAB9ANPC1STAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 CA1 2406/4885CA2 2764/4885CA4 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.